Previous 10 | Next 10 |
AtriCure Inc. (ATRC) is expected to report $-0.3 for Q3 2023
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2023 Healthcare Conference. ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2023 financial results on Wednesday, N...
2023-09-04 12:21:00 ET Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. The investment bank noted that medtech growth slowed slightly in Q2, expanding by only 8.3% co...
2023-08-29 22:32:23 ET Summary AtriCure stock has been heavily sold off following its Q2 numbers, despite strong performance and a revised full-year outlook. The company has seen growth across all segments, with around 20% growth and profits posted at the adj. EBITDA line. Val...
2023-07-25 19:40:03 ET AtriCure, Inc. (ATRC) Q2 2023 Earnings Conference Call July 25, 2023 04:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin Group Mike Carrel - President & CEO Angie Wirick - CFO Conference Call Participants ...
2023-07-25 16:13:00 ET AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.11 beats by $0.19 . Revenue of $100.9M (+19.4% Y/Y) beats by $3.41M . For further details see: AtriCure GAAP EPS of -$0.11 beats by $0.19, revenue of $100.9M beats by $3.41M
Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvem...
2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 2...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...